Amarin Corporation plc (“Amarin”) is a pharmaceutical company which develops and commercializes therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Kessler Topaz Meltzer & Check, LLP (“KTMC”) is investigating potential claims on behalf of purchasers of Amarin (Nasadq: AMRN) securities between February 27, 2018 and March 31, 2020.
KTMC’s investigation is related to a recent decision in Amarin’s lawsuit against generic drug manufacturers that filed applications with the FDA to produce generic versions of Vascepa, in which the judge ruled that Amarin’s patents were invalid.
Amarin investors may receive additional information about the case by clicking the link "Submit Your Information" above and fill out the form as promptly as possible.
If you wish to discuss this investigation or have any questions concerning your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP toll free at 1-844-887-9500 or 1-610-667-7706, or via e-mail at info@ktmc.com.
CONTACT:
Kessler Topaz Meltzer & Check, LLP
James Maro, Esq. or Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087
1-844-887-9500 (toll free) or 1-610-667-7706
Or by e-mail at info@ktmc.com